A Director at Adamis Pharma (NASDAQ: ADMP) is Buying Shares

By Carrie Williams

Today, a Director at Adamis Pharma (ADMPResearch Report), William Denby, bought shares of ADMP for $9,937.

Following this transaction William Denby’s holding in the company was increased by 6.1% to a total of $163.1K. In addition to William Denby, 2 other ADMP executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Adamis Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $4.91 million and GAAP net loss of $8.89 million. In comparison, last year the company earned revenue of $3.18 million and had a GAAP net loss of $7.62 million. Currently, Adamis Pharma has an average volume of 300.3K.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $5.30, reflecting a 255.7% upside.

The insider sentiment on Adamis Pharma has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets.